eligibility_summary
Inclusion: life expectancy >3 mo, measurable disease, prior AEs ≤G1, adequate marrow/organ function, QTcF <500 ms, relapsed/progressed after SOC or no options. Cohorts: A/B high‑grade serous ovarian, fallopian tube, or primary peritoneal, C epithelial endometrial (post ≥1 platinum or IO, ≤3 lines), D NSCLC (per prior-therapy rules, ≤4 lines), E TNBC (ER/PR <1%, HER2‑neg, 1–4 lines). Exclude: prior tubulin‑ADC or FolRα drugs, mAb allergy, recent therapy/major surgery, ocular disease, need folate supplements.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: STRO-002 (luveltamab tazevibulin), a biological antibody–drug conjugate (ADC). Mechanism of action: a humanized monoclonal antibody binds folate receptor alpha (FOLRα) on tumor cells, is internalized, and releases a cleavable cytotoxic payload that inhibits microtubules/tubulin, causing mitotic arrest and apoptosis. Trial focuses on monotherapy dose escalation/expansion in Chinese adults. Targets: FOLRα-overexpressing epithelial tumors—ovarian, endometrial, NSCLC, and triple-negative breast cancer—selected by IHC tumor proportion score thresholds. Pathways/cells affected: FOLRα-positive cancer cells via receptor-mediated endocytosis, microtubule dynamics/mitotic spindle function.